Literature DB >> 21931205

Serum interleukin-23 levels in patients with ulcerative colitis.

Mojgan Mohammadi1, Mohammad Mahdi Hayatbakhsh, Mohammad Javad Zahedi, Mahmood Reza Jalalpour, Amin Pakgohar.   

Abstract

BACKGROUND: Patients with ulcerative colitis are at increased risk of inflammation. Interleukin 23 (IL-23) is a newly identified cytokine with increased expression in inflamed biopsies of colon mucosa in patients with Crohn's disease; however, there is inconsistent evidence on its role in ulcerative colitis.
OBJECTIVE: We aimed to compare serum IL-23 level in patients with ulcerative colitis and normal controls and determine if serum IL-23 level increases with the severity of disease according to endoscopic findings.
METHODS: We quantified serum IL-23 levels from 60 patients with ulcerative colitis and 20 control individuals. All patients underwent endoscopic procedure to define the severity of disease. Patients were then stratified into 2 groups of "Mild" and "Severe" according to the endoscopic findings.
RESULTS: For comparison of serum IL-23 levels, Platelet count, ESR and CRP between the groups, Mann-Whitney U test and independent sample t test were employed, as appropriate. Pearson's and spearman's correlation tests were employed to test the association of IL-23 with platelet count, CRP and ESR in patients. Our findings showed that serum IL-23 levels were increased in patients with ulcerative colitis compared to normal controls. Moreover, patients in "Severe" group had higher serum IL-23 levels and ESR compared with those in "Mild" group. There was no significant sexual dimorphism in any of studied variables.
CONCLUSION: We suggest that IL-23 plays an important role in the pathogenesis of ulcerative colitis and is a marker of disease activity in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931205     DOI: IJIv8i3A6

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  5 in total

1.  Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results.

Authors:  Tamer A Gheita; Iman I El Gazzar; Hussein S El-Fishawy; Mohamed A Aboul-Ezz; Sanaa A Kenawy
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

2.  Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis.

Authors:  Qin Zhu; Peifen Zheng; Xinyu Chen; Feng Zhou; Qiaona He; Yuefeng Yang
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

3.  Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection.

Authors:  Julajak Limsrivilai; Krishna Rao; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Andrew Reinink; Laura Johnson; Emily Briggs; Peter D R Higgins
Journal:  Dig Dis Sci       Date:  2018-04-12       Impact factor: 3.199

4.  Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease.

Authors:  Katarzyna Fischer; Hanna Przepiera-Będzak; Marcin Sawicki; Anna Walecka; Iwona Brzosko; Marek Brzosko
Journal:  Mediators Inflamm       Date:  2017-12-21       Impact factor: 4.711

5.  Evaluation of IL-12A, IL-12B, IL-23A and IL-27 mRNA expression level genes in peripheral mononuclear cells of inflammatory bowel disease patients in an Iranian population.

Authors:  Mohsen Norouzinia; Vahid Chaleshi; Samaneh Alinaghi; Saeedeh Sadat Beheshti Shirazi; Aliasghar Keramatinia; Mahyar Nourian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.